A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

Summary

This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes

Eligibility

Inclusion Criteria:

* ○ Have been diagnosed with type 2 diabetes mellitus (T2DM);

  * Be on stable treatment with unchanged dose of metformin ≥1500 mg/day or \<1500 mg/day but ≥1000 mg/day (the maximum tolerated dose) for at least 8 weeks prior to screening
  * Have a BMI ≥23 kilograms per meter squared (kg/m²) at screening;
  * Be of stable weight (± 5%) for at least 3 months before screening;
  * Have HbA1c between ≥7.5% and ≤11.0% at screening

Exclusion Criteria:

* ○ Previous diagnosis of type 1 diabetes, special type diabetes;

  * Have suffered the malignancy within the past 5 years (except cured basal cell carcinoma of the skin, cervical carcinoma in situ), or being evaluated for an underlying malignancy;
  * Have the acute or chronic pancreatitis;
  * Known to be allergic to 3 or more kinds of foods or medications, or allergic to GLP-1 agonist or metformin, or have a severe allergic disease (asthma, urticaria, eczematous dermatitis, etc.) at screening;
  * Have a serious mental illness or speech impediment and be unable to fully understand the study;
  * Suspected or confirmed history of alcohol or drug abuse;
  * Have had a history of ≥2 severe hypoglycemic episodes in the past 1 year;
  * Other conditions that may impact the assessment of investigational products, as determined by the Investigator.

Conditions2

Interventions2

Related trials

• A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver — Boehringer Ingelheim
• A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) — Actimed Therapeutics Ltd
• A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus — Eli Lilly and Company
• COMMETS- Combination MCI Metabolic Syndrome — Rutgers, The State University of New Jersey
• Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes — Mostafa Bahaa
• GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM — Federico II University
• Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes — Steno Diabetes Center Copenhagen
• Probiotic Intervention on Body Weight — Chinese Academy of Sciences

Browse More Trials